Genentech
FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek
FoundationOne Liquid CDx, a liquid biopsy test, is the only blood-based CDx approved for the targeted cancer therapy.
Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq
The test gained European approval to identify PD-L1-expressing non-small cell lung cancer patients eligible for treatment with Roche's checkpoint inhibitor.
In Brief This Week: PerkinElmer, Chembio, Becton Dickinson, Fulgent Genetics, and More
News items for the in vitro diagnostic industry for the week of Sept. 20, 2021.
Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor
The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.
Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.